Status:
COMPLETED
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily...
Eligibility Criteria
Inclusion
- Type 1 diabetes for at least 12 months
- Current daily insulin dose of more than 1.4 IU/kg
- BMI lesser than or equal to 35 kg/m2
- HbA1c greater than 7.5% and less than or equal to 12.0%
- In Austria, age more than 19 years
Exclusion
- Proliferate retinopathy or maculopathy
- Recurrent major hypoglycaemia
- Any condition or disease such as uncontrolled hypertension or AIDS/HIV that rule out trial participation according to the judgement of the investigator
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2003
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT00312104
Start Date
April 1 2002
End Date
March 1 2003
Last Update
January 27 2017
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Graz, Austria, 8036
2
Novo Nordisk Investigational Site
Vienna, Austria, 1030
3
Novo Nordisk Investigational Site
Vienna, Austria, 1090
4
Novo Nordisk Investigational Site
Vienna, Austria, A 1160